Cyclopentamine
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Cyclopentamine
- DrugBank Accession Number
- DB08999
- Background
Cyclopentamine is a sympathomimetic alkylamine, classified as a vasoconstrictor. Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia. It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.
- Type
- Small Molecule
- Groups
- Withdrawn
- Structure
- Weight
- Average: 141.258
Monoisotopic: 141.151749616 - Chemical Formula
- C9H19N
- Synonyms
- Cyclopentamine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Cyclopentamine. Acetyl sulfisoxazole The risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Cyclopentamine. Bendroflumethiazide The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclopentamine. Benzthiazide The risk or severity of adverse effects can be increased when Benzthiazide is combined with Cyclopentamine. Bethanechol The risk or severity of hypotension can be increased when Cyclopentamine is combined with Bethanechol. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cyclopentamine hydrochloride F551446KF3 538-02-3 XGZPRABQSGUFBL-UHFFFAOYSA-N
Categories
- ATC Codes
- R01AA02 — Cyclopentamine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as dialkylamines. These are organic compounds containing a dialkylamine group, characterized by two alkyl groups bonded to the amino nitrogen.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Dialkylamines
- Alternative Parents
- Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Aliphatic homomonocyclic compound / Hydrocarbon derivative / Organopnictogen compound / Secondary aliphatic amine
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WB9Q6M8O60
- CAS number
- 102-45-4
- InChI Key
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H19N/c1-8(10-2)7-9-5-3-4-6-9/h8-10H,3-7H2,1-2H3
- IUPAC Name
- (1-cyclopentylpropan-2-yl)(methyl)amine
- SMILES
- CNC(C)CC1CCCC1
References
- Synthesis Reference
U.S. Patent 2,520,015.
- General References
- Not Available
- External Links
- KEGG Drug
- D07370
- PubChem Compound
- 7608
- PubChem Substance
- 310264960
- ChemSpider
- 7326
- BindingDB
- 81456
- 59094
- ChEBI
- 134766
- ChEMBL
- CHEMBL329203
- Wikipedia
- Cyclopentamine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 113-115 U.S. Patent 2,520,015. - Predicted Properties
Property Value Source Water Solubility 0.476 mg/mL ALOGPS logP 2.86 ALOGPS logP 2.26 Chemaxon logS -2.5 ALOGPS pKa (Strongest Basic) 10.61 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 12.03 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 44.93 m3·mol-1 Chemaxon Polarizability 18.4 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0aor-9200000000-60876689abb067d5f0b9 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-006x-9800000000-a936f00330acc88e4893 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0900000000-646c482fb0db47bdb610 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4l-0900000000-1062346c667a8cc036a1 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-9100000000-21f977a86bb385f4f476 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4l-9000000000-36bef58a78ee37c3b266 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9500000000-3db0d0d174f61ff6d79a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 136.22264 predictedDeepCCS 1.0 (2019) [M+H]+ 138.63011 predictedDeepCCS 1.0 (2019) [M+Na]+ 147.45888 predictedDeepCCS 1.0 (2019)
Drug created at June 17, 2014 15:42 / Updated at February 21, 2021 18:52